Horizon Discovery Signs License Agreement with ProteoNic B.V. for the Provision of Expression Vectors Alongside Horizon Bioproduction Cell Lines

Cambridge, UK, 7 June 2016: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), the world leader in the application of gene editing technologies including bioproduction cell lines, today announces it has entered into a non-exclusive Licensing Agreement with ProteoNic B.V. to provide the CHOGUN expression vector to customers alongside Horizon’s HD-BIOP3 GS Null CHO cell line as standard, providing a powerful and…